Plunkett Research Online: BerGenBio ASA

BERGENBIO ASA (BRRGF:PINX) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

BerGenBio ASA is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers......



BerGenBio ASA
Ticker: BRRGF
Exchange: PINX
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 47 53501564
Fax:
Address: Jonas Lies vei 91
Bergen, 5009 Norway

Types Of Business
Industry Ranks

Industry NAICS code:

Biotechnology

Ranks not available
ContactsDescription

BerGenBio ASA is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers......See More See More

Auditor: Ernst & Young AS
Legal Advisor:
$USD, In whole numbers,
except marked * or %
20192018201720162015
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: